The Pink Pill vs. The Blue Pill: Why Women Had to Fight for Desire

Take the HSDD quiz: https://addyi.com/quiz/

There’s a medication designed to help women with low sexual desire, and despite existing for years, most people still know almost nothing about it.

Meanwhile, nearly everyone knows what Viagra is.

That alone says a lot.

On a recent episode of Taboo Talk: Not Safe for Brunch, we dug into the complicated history behind Addyi, commonly nicknamed “the pink pill,” and why its journey has been dramatically different from Viagra’s from the very beginning.

And once you start looking into it, the double standards become impossible to ignore.

Watch our YouTube Episode on the Pink Pill: https://youtu.be/UK-BnrPvD44

First Things First: Addyi Is NOT “Female Viagra”

The comparison sounds simple, but medically, these drugs are doing completely different things.

Viagra works by increasing blood flow to help men physically respond during sex. It treats erectile dysfunction, which is considered a measurable physical condition.

It does not create desire.

If a man has zero interest in sex, Viagra doesn’t magically create that interest. It simply supports the body’s physical response if the desire is already there.

Addyi works completely differently.

Addyi is a non-hormonal medication that works on brain chemistry involving dopamine and serotonin. It’s designed to help women experiencing HSDD, or hypoactive sexual desire disorder.

That means persistent low sexual desire that causes distress.

This isn’t about occasionally being tired, stressed, or “not in the mood.” It’s about women who once had desire and feel like it disappeared.

And unlike Viagra, Addyi is taken daily, not just before sex.

The Approval Process Was Wild

Here’s where things start getting frustrating.

Viagra was quickly embraced as a major medical breakthrough. Erectile dysfunction was seen as a serious issue worth solving immediately.

Addyi?

Not so much.

Research into flibanserin, the drug behind Addyi, started back in 1999. Interestingly, it was originally studied as an antidepressant before researchers noticed it affected sexual desire.

Sound familiar?

That’s basically the same accidental discovery story Viagra had.

But while Viagra moved quickly through approvals and became normalized almost overnight, Addyi faced repeated rejections.

Even after clinical trials showed statistically meaningful improvements in desire and sexual satisfaction, the FDA rejected it multiple times.

One of the concerns discussed heavily during the approval process?

Women might feel tired the next day while driving children to school.

Meanwhile, medications prescribed to men regularly carry risks too, including vision problems and cardiovascular concerns, yet those conversations rarely become public moral debates.

That’s the part that frustrated a lot of people watching the Addyi documentary.

The message women kept hearing was:
“Do women really need sexual desire badly enough to treat it medically?”

And honestly, that’s a pretty telling question.

Women Literally Had to Publicly Defend Their Right to Desire

One of the most emotional parts of the story is how far women had to go to advocate for Addyi.

Women involved in clinical trials publicly testified about how losing sexual desire impacted their relationships, confidence, and emotional well-being.

They had to openly discuss deeply personal struggles in front of approval panels just to convince people this mattered.

That should never have been necessary.

Especially considering how normalized erectile dysfunction medications became for men.

Today, it’s incredibly common for men to casually discuss Viagra or Cialis. Some doctors reportedly offer prescriptions proactively once men reach a certain age.

Meanwhile, women are still struggling to even have conversations about low desire without shame attached.

There’s Also a Bigger Problem Here

The reality is that women’s sexual desire is complicated.

Stress.
Mental health.
Hormones.
Relationship dynamics.
Exhaustion.
Parenthood.
Body image.
Medication side effects.

All of these things can affect libido.

Antidepressants are a huge example. Many SSRIs are known to reduce sexual desire significantly for women. Some women describe feeling emotionally numb or disconnected from sexual pleasure entirely.

That creates a difficult balancing act:
Protecting mental health while also preserving intimacy and desire.

And this is where Addyi gets misunderstood.

It isn’t designed to instantly “fix” someone’s sex life overnight. It’s meant to support desire over time while women also address the bigger picture around stress, relationships, hormones, and emotional well-being.

Why Addyi Didn’t Become the “Next Viagra”

Honestly? Expectations played a huge role.

People expected Addyi to work like Viagra:
Take pill.
Feel immediate results.
Problem solved.

That’s not what happens.

Addyi requires consistency. It’s taken daily at bedtime, and results may take weeks. Some women notice improvements within four weeks, while others need longer.

Clinical trials showed women experienced roughly 0.5 to 1 additional satisfying sexual experience per month compared to placebo.

At first glance, that sounds small.

But for someone experiencing complete loss of desire, even a small shift can feel life-changing.

Especially when intimacy has become something tied to obligation instead of genuine connection.

The Bigger Takeaway

The real conversation isn’t just about one medication.

It’s about how differently society has approached men’s and women’s sexual health for decades.

Men’s sexual dysfunction was framed as urgent, physical, measurable, and important.

Women’s sexual dysfunction was framed as emotional, complicated, controversial, and questionable.

That difference shaped everything:
Research funding.
Public conversation.
Medical acceptance.
Advertising.
Prescriptions.
Education.

And even now, many people still don’t know Addyi exists.

Maybe the issue was never that women’s desire was “too complicated” to treat.

Maybe it’s that women’s desire was never taken seriously enough in the first place.